

Substitute for form 1449A-B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Complete if Known	
	Application Number	10/084,706 10/609,296
	Filing Date	February 26, 2002 June 27, 2003
	First Named Inventor	Rasmussen, et al.
	Group Art Unit	1647
	Examiner Name	J. Seharaseyon
	Attorney Docket Number	0228us410 0228us420

U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code (if known)		

FOREIGN PATENT DOCUMENTS								
Examiner Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (if known)				
/JS/	1	EP	0 287 075	B2	Dr. Rentschler Biotechnologie GmbH	10/19/1988		X
/JS/	2	EP	0 287 075 (English language translation of document AY)	B2	Dr. Rentschler Biotechnologie GmbH	10/19/1988		
/JS/	3	WO	01/15736	A2	Maxygen ApS	03/08/2001		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T
/JS/	4	O'CONNELL, et al., "The Influence of Flanking Sequences on O-Glycosylation", <i>Biochemical and Biophysical Research Communications</i> , 1991, pp. 1024-1030, 180:2.			

Examiner Signature	/Jegatheesan Seharaseyon/	Date Considered	08/15/2007
-----------------------	---------------------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Copy from Parent Application

Substitute for form 1449A-B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>	Complete if Known	
	Application Number	09/648,569 10/609,296
	Filing Date	August 25, 2000 June 27, 2003
	First Named Inventor	A.-H. Pedersen Poul B. Rasmussen
	Group Art Unit	1647
	Examiner Name	J. Seharaseyon
	Attorney Docket Number	0202us810 0228us420

U.S. PATENT DOCUMENTS						
Examiner Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code (if known)			
/JS/	1	5,206,344		Katre et al.	04/27/1993	
/JS/	2	5,738,846		Greenwald et al.	04/14/1998	

FOREIGN PATENT DOCUMENTS								
Examiner Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (if known)				
/JS/	3	EP	0 370 205	A2	Kyowa Hakko Kogyo Co., Ltd.	05/30/1990		
	4	EP	0 529 300	B1	Rentschler Biotechnologie GmbH & Co.	03/03/93		X
	5	EP	0 529 300 (English language translation of document #4)	B1	Rentschler Biotechnologie GmbH & Co.	03/03/93		
	6	WO	95/27502	A1	Research Develop- ment Foundation	10/19/1995		
	7	WO	98/35026	A1	Novo Nordisk A/S	08/13/1998		
	8	WO	99/55377	A2	Applied Research Systems	11/04/1999		

OTHER ART - NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T
/JS/	9	Derwent Abstract 012152872 for WO 98/48018, a German publication cited in previous IDS Form-1449.				
/JS/	10	Derwent Abstract 009442954 for EP 539 300, a French publication cited in previous IDS Form-1449.				

Examiner Signature	/Jegatheesan Seharaseyon/	Date Considered	08/15/2007
-----------------------	---------------------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

COPY FROM PARENT

(Modified) PTO/SB/08A-B (10-96)
Approved for use through 10/31/99. OMB 0651-0031

Substitute for form 1449A-B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

COPY FROM PARENT

Complete if Known

Application Number	09/048,569 10/609,296
Filing Date	August 25, 2000 June 27, 2003
First Named Inventor	Anders Hjeltholt Pedersen Povl Rasmussen
Group Art Unit	1639-1647
Examiner Name	Unassigned J. Seharaseyon
Attorney Docket Number	31-107600US 0228 US 420

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code (if known)			
JS/	AA	4,588,585		Mark et al.	05-13-1986	
	AB	4,686,191		Itoh et al.	08-11-1987	
	AC	4,769,233		Bell et al.	09-06-1988	
	AD	4,904,584		Shaw	02-27-1990	
	AE	4,914,033		Bell et al.	04-03-1990	
	AF	4,917,888		Katre et al.	04-17-1990	
	AG	4,966,843		McCormick et al.	10-30-1990	
	AH	5,218,092		Sasaki et al.	08-06-1993	
	AI	5,376,567		McCormick et al.	12-27-1994	
	AJ	5,382,657		Hoffmann-La Roche Inc.	01-17-1995	
↓	AK	5,545,723		Goelz et al.	08-13-1996	
	AL	5,795,779		McCormick et al.	08-18-1998	

FOREIGN PATENT DOCUMENTS

Examin er Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (if known)				
JS/	AM	WO	95/25170		Biogen, Inc.	09-21-1995		
	AN	WO	98/48018		Fraun-Hofer- Gesellschaft Zur Forderung Der Angewandten	10-29-1998		
	AO	WO	99/03887		Bolder Biotechnology	01-28-1999		
	AP	WO	99/55377		Applied Research	11-04-1999		
	AQ	WO	99/67291		Immunex Corporation	12-29-1999		
	AR	WO	00/23114		Biogen, Inc.	04-27-2000		

Examiner Signature	/Jegatheesan Seharaseyon/	Date Considered	08/15/2007
-----------------------	---------------------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

COPY FROM PARENT

(Modified) PTO/SB/08A-B (10-96)
Approved for use through 10/31/99. OMB 0651-0031

Substitute for form 1449A-B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Complete if Known	
	Application Number	09/648,569 10/609, 296
	Filing Date	August 25, 2000 June 27, 2003
	First Named Inventor	Anders, Hjelholt Pedersen Paul Rayhusen
	Group Art Unit	1633/647
	Examiner Name	Unassigned J. Scharaseyov
Attorney Docket Number	31-107600US-022Plus 420	

JS/	AS	WO	00/23472	Biogen, Inc.	04-27-2000		
	AT	WO	00/26354	Novo Nordisk	05-11-2000		
	AU	EP	083 069	Kyowa Hakko Kogyo Co., Ltd.	09-16-1987		
	AV	EP	041 313	Biogen, Inc.	09-12-1990		
	AW	EP	229 108	Cetus Corporation	12-27-1990		
	AX	EP	260 350	Cetus Corporation	02-12-1992		
	AY	EP	287 075	Arszeneimittelforschung /Drug Research	01-18-1995		
	AZ	EP	539 300	Philippe Thiriet	02-07-1996		
↓	BA	EP	593 868	Hoffmann-La Roche Inc.	04-15-1998		

OTHER PRIOR ART - NON PATECNT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
JS/	BB	Fierbeck et al., "Neutralising interferon β antibodies in melanoma patients treated with recombinant and natural interferon β " <u>Cancer Immunol Immunother</u> (1994) 39:263-268	
	BC	Karpusas et al., "The Structure of Human Interferon- β : Implications for activity" <u>CMLS</u> 54 (1998) 1203-1216	
	BD	Karpusas et al. "The crystal structure of human interferon β at 2.2 A resolution" <u>Proc. Nat. Acad. Sci. USA</u> (1997) 94:11813-11818	
	BE	Mayorga et al., "Antibodies to Commercially Available Interferon-Bet Molecules in Multiple Sclerosis Patients Treated with Natural Interferon-Beta" <u>Int. Arch. Allergy Immunol</u> 1999; 118:368-371	
	BF	Munschauer et al., "Managing Side Effects of Interferon-Beta in Patients with Relapsing-Remitting Multiple Sclerosis" <u>Clinical Therapeutics</u> vol. 19, No. 5, 1997 883-893	
↓	BG	Redlich et al., "Antibodies that neutralize human β interferon biologic activity recognizing a linear epitope: Analysis by synthetic peptide mapping" <u>Proc. Natl. Acad. Sci. USA</u> vol. 88, pp. 4040-4044 May 1991	

Examiner Signature	/Jegatheesan Seharaseyov/	Date Considered	08/15/2007
--------------------	---------------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A-B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Complete if Known	
	Application Number	09/648,569 10/609,296
	Filing Date	August 25, 2000 June 27, 2003
	First Named Inventor	Anders, Hjeltnet Pedersen Paul Rasmussen
	Group Art Unit	1633 1647
	Examiner Name	Unassigned J. Seharaseyon
	Attorney Docket Number	31-107600US 0228 us 420

JS	BH	Rudick et al., "Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis" <u>Neurology</u> May 1889, 50: 1266-1272	
	BI	Runkel et al., "Structural and Functional Differences Between Glycosylated and Non-Glycosylated Forms of Human Interferon- β (IFN- β)" <u>Pharmaceutical Research</u> vol. 15, No 4, 1998, 641-649	
	BJ	Runkel et al, 1998, Jour. Biol. Chem. Difference in Activity between α and β Type I Interferons Explored by Mutational Analysis" 273, No. 14, pp. 8003-8008	
	BK	Senda et al., "Refined Crystal Structure of Recombinant Murine Interferon- β at 2.15 A Resolution" <u>J. Mol. Biol.</u> (1995) 253, 187-207	
	BL	Stewart et al, DNA "Chemical Mutagenesis of Human Interferon- β : Construction, Expression in E. coli, and Biological Activity of Sodium Bisulfite-Induced Mutations Vol 6 no 2 1987 p119-128	
	BM	Taniguchi, et al., "The nucleotide sequence of human fibroblast interferon cDNA" <u>Gene</u> 10 (1980) 11-15	
	BN	Yong et al., "Interferon beta in the treatment of multiple sclerosis" <u>Neurology</u> 1998; 51: 682-689	

Examiner Signature	/Jegatheesan Seharaseyon/	Date Considered	08/15/2007
--------------------	---------------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Substitute for form 1449A-B/PTO SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>	Complete if Known	
	Application Number	10/609,296
	Filing Date	June 27, 2003
	First Named Inventor	Poul Baad Rasmussen
	Group Art Unit	1647
	Examiner Name	Jegatheesan Seharaseyon
Attorney Docket Number	0228us420	

U.S. PATENT DOCUMENTS						
Examiner Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, lines, Where Relevant Passages or Relevant Figures Appeal
		Number	Kind Code (if known)			
/JS/	1	6,531,122		Pedersen et al.	03-11-2003	
/JS/	2	2003/0175240A1 (USSN 10/325,720)		Pedersen et al.	09-18-2003	
/JS/	3	2003/0170206A1 (USSN 10/084,706)		Rasmussen et al.	09-11-2003	

FOREIGN PATENT DOCUMENTS								
Examiner Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (if known)				

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T
/JS/	4	Apweiler et al., "On the frequency of protein glycosylation, as deduced from analysis of the SWISS-PROT database," Biochim. Biophys. Acta 1473:4-8 (1999).			
/JS/	5	Wells et al., "Additivity of Mutational Effects in Proteins," Biochemistry 29(37):8509-8517 (1990).			
/JS/	6	Ngo et al., "Computation Complexity, Protein Structure Prediction, and the Levinthal Paradox," in THE PROTEIN FOLDING PROBLEM AND TERTIARY STRUCTURE PREDICTION, pp. 492-495 (K. Merz Jr. and S. Le Grand, eds., 1994).			

Examiner Signature	/Jegatheesan Seharaseyon/	Date Considered	08/15/2007
-----------------------	---------------------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.